1 / 15

The impact of PBS co-payment increases on the use of prescription medicines

The impact of PBS co-payment increases on the use of prescription medicines. Centre for Health Services Research UWA School of Population Health ACERH Policy Forum, 2009. Acknowledgements. Pharmaceutical Benefits Scheme (PBS) Co-payments.

alessa
Télécharger la présentation

The impact of PBS co-payment increases on the use of prescription medicines

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The impact of PBS co-payment increases on the use of prescription medicines Centre for Health Services Research UWA School of Population Health ACERH Policy Forum, 2009

  2. Acknowledgements

  3. Pharmaceutical Benefits Scheme (PBS)Co-payments • The PBS accounts for more than 90% of the prescription medicines dispensed in Australia • Patients contribute a co-payment toward the cost of each of their prescriptions • Different co-payments levels: • General beneficiaries • Concessional beneficiaries

  4. PBS co-payment changes • Study Focus: • PBS co-payments increase incrementally • Largest co-payment increase (~24%) in January 2005 • Concessional $3.70 → $4.60 • General $23.10 → $28.60 • Unknown effect on: • medication use • health care contact • hospitalisation • mortality

  5. Impact of rising medicine costs • When patients have difficulty meeting prescription costs they may modify, reduce, or cease their medication use1,2 • Recent surveys of Australians in poor health reported that one-fifth had not filled a prescription due to cost3,4 1Chubon et al., Public Health Nurs 1994; 11: 412-415. 2Strickland & Hanson, J Health Care Poor Underserved 1996; 7: 50-62. 3Schoen et al., Health Aff2005; 24: w509-w525. 4Blendon et al., Health Aff 2003; 22: 106-121.

  6. Medicined examined • 17 medicine classes examined • - symptomatic vs. asymptomatic conditions • - essential vs. discretionary medicines • Anti-epileptics • Hypnotics • Anti-gout treatments • Insulin • Anti-Parkinson’s • Muscle relaxants • Anxiolytics • Non-aspirin antiplatelets • Atypical antipsychotics • Osteoporosis treatments • Beta-blockers for heart failure • PPIs • Combination asthma medicines • Statins • Eye drops (non-essential) • Thyroxine • Glaucoma treatments

  7. Data analyses • Dispensed prescription counts for WA and Australia for each month between January 2000 and September 2007 • Defined daily dose (DDD) • Interrupted time-series analysis comparing dispensing trends before and after January 2005 -The percentage change in dispensings was calculated for each medicine category and beneficiary group

  8. Changes in PBS medication dispensing after co-payment increase (WA) Proton pump inhibitors Significant decreases in both the level (p<0.001) and the trend (p<0.001) of dispensing after the 2005 co-payment increase Hynd, Preen, Roughead, Glover, Semmens. ANZ J Pub Health 2008; In Press.

  9. Changes in PBS medication dispensing after co-payment increase (WA) Antipsychotics No significant decrease in either the level or the trend after the 2005 co-payment increase Hynd, Preen, Roughead, Glover, Semmens. ANZ J Pub Health 2008; In Press.

  10. Changes in PBS medication dispensing after co-payment increase (WA) Statins The level decreased by 3053 prescriptions (P = 0.023) The trend decreased by 151 prescriptions per month (a 6.3% decrease) (P = 0.018) Hynd, Preen, Roughead, Glover, Semmens. ANZ J Pub Health 2008; In Press.

  11. Percentage change in prescription volumes(Australia) † General beneficiaries P<0.001 * Concessional beneficiaries P<0.001 Hynd, Preen, Roughead, Glover, Bulsara, Semmens. Pharmacoepi Drug Safety 2008; 17(11): 1091-99.

  12. Summary of findings (Australia) • No change, or increases for: - anti-gout treatments - beta-blockers for heart failure - anxiolytics - hypnotics - atypical antipsychotics • Level only decreases for: • thyroxine - insulin • Trend, or level and trend, decreases for: - anti-epileptics - muscle relaxants - anti-Parkinson’s - non-aspirin antiplatelets - combination asthma - osteoporosis treatments - eye drops - PPIs - glaucoma treatments - statins Hynd, Preen, Roughead, Glover, Bulsara, Semmens. Pharmacoepi Drug Safety 2008; 17(11): 1091-99.

  13. Where to next? • Unknown effect of policy change on: • Patients using multiple medications (≥5 per month) • Medication persistence • Adverse health events • Unplanned hospitalisation • Mortality • Health care costs • Linked hospital morbidity, death, PBS & MBS data (2000-2007)

  14. Thankyou

More Related